Lauren McLaughlin
Overview
Explore the profile of Lauren McLaughlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiu S, Fowler S, Bridges S, Hanson N, King J, Street S, et al.
Can J Surg
. 2024 Mar;
67(2):E77-E84.
PMID: 38453350
Background: The Delta Oasis program was launched in New Brunswick in 2006 to offer patients from rural areas who were undergoing breast cancer surgery and their families 1 night of...
2.
Bridges S, Fowler S, McLaughlin L, Robichaud M, Ridgway B, Reece D, et al.
Res Involv Engagem
. 2023 Jul;
9(1):60.
PMID: 37516883
Background: Over the last decade there has been considerable research into the treatment, management, and quality of life of people living with multiple myeloma. However, there has been limited investigation...
3.
Chaudhuri S, Ben Chaouch Z, Hauber B, Mange B, Zhou M, Christopher S, et al.
J Biopharm Stat
. 2023 Mar;
:1-20.
PMID: 36861942
A fixed one-sided significance level of 5% is commonly used to interpret the statistical significance of randomized clinical trial (RCT) outcomes. While it is necessary to reduce the false positive...
4.
Fowler S, McLaughlin L, Bridges S, Robichaud M, Ridgway B, Reece D, et al.
Br J Haematol
. 2021 Nov;
196(5):e52-e54.
PMID: 34741302
No abstract available.
5.
Benz H, Caldwell B, Ruiz J, Saha A, Ho M, Christopher S, et al.
MDM Policy Pract
. 2021 Jul;
6(1):23814683211021380.
PMID: 34277950
A growing literature has developed on identifying outcomes that matter to patients. This study demonstrates an approach involving patient and regulatory perspectives to identify outcomes that are meaningful in the...
6.
Hauber B, Mange B, Zhou M, Chaudhuri S, Benz H, Caldwell B, et al.
MDM Policy Pract
. 2021 Feb;
6(1):2381468320978407.
PMID: 33521289
Parkinson's disease (PD) is neurodegenerative, causing motor, cognitive, psychological, somatic, and autonomic symptoms. Understanding PD patients' preferences for novel neurostimulation devices may help ensure that devices are delivered in a...
7.
Heusinkveld L, Hacker M, Turchan M, Bollig M, Tamargo C, Fisher W, et al.
J Parkinsons Dis
. 2016 Dec;
7(1):89-94.
PMID: 27911344
The FDA has approved a multicenter, double-blind, Phase III, pivotal trial testing deep brain stimulation (DBS) in 280 people with very early stage Parkinson's disease (PD; IDE#G050016). In partnership with...
8.
Llaurador G, McLaughlin L, Wistinghausen B
Curr Opin Pediatr
. 2016 Dec;
29(1):34-40.
PMID: 27906865
Purpose Of Review: Post-transplant lymphoproliferative disease (PTLD) is a major complication of hematopoietic stem cell and solid organ transplantation. The incidence of transplantation in childhood has been steadily rising, making...
9.
McLaughlin L, Cruz C, Bollard C
Ther Adv Hematol
. 2015 Dec;
6(6):295-307.
PMID: 26622998
Despite significant advancements in the treatment and outcome of hematologic malignancies, prognosis remains poor for patients who have relapsed or refractory disease. Adoptive T-cell immunotherapy offers novel therapeutics that attempt...
10.
Gamble R, Jensen D, Suarez A, Hanson A, McLaughlin L, Duke J, et al.
Cancers (Basel)
. 2013 Nov;
2(2):1178-97.
PMID: 24281112
Health care providers and their patients jointly participate in melanoma prevention, surveillance, diagnosis, and treatment. This paper reviews screening and follow-up strategies for patients who have been diagnosed with melanoma,...